首页> 美国卫生研究院文献>Molecular Imaging and Radionuclide Therapy >Effectiveness of Fixed Dose Radioactive Iodine (RAI) for the Treatment of Hyperthyroidism: Experience of a Teaching Hospital in South West Nigeria
【2h】

Effectiveness of Fixed Dose Radioactive Iodine (RAI) for the Treatment of Hyperthyroidism: Experience of a Teaching Hospital in South West Nigeria

机译:固定剂量放射性碘(RAI)治疗甲亢的有效性:尼日利亚西南部一家教学医院的经验

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Objective: Using radioactive iodine (RAI) as the first line therapy for Graves’ hyperthyroidism and as the treatment of choice for relapsed Graves’ disease is increasing in recent times. However, there has been little consensus on the most appropriate dose to use. So this study is to determine the response of hyperthyroidism to fixed doses of 370 MBq and 555 MBq RAI therapies and determine the incidence of hypothyroidism at 6 months post therapy.>Methods: Hyperthyroid patients’ case records treated with radioiodine was retrospectively reviewed to determine the response rate of hyperthyroidism to the two fixed dose regimens. Statistical analysis was done with SPSS version 15.0 and the level of statistical significance was taken as p<0.05. Forty subjects, 6 males (15%) and 34 females (85%) received RAI therapy for Graves’ hyperthyroidism, mean age was 49.4 years (range, 25-75years). The thyroid function status at 6 months post therapy was available for all subjects. 24 patients (60%) received 370 MBq while 16 patients (40%) received 555 MBq.>Results: The response for fixed doses of 370 MBq and 555 MBq were similar (100%). Also, the incidence of hypothyroidism in these subjects which was 66.6% with fixed dose of 370 MBq and 62.5% with fixed dose of 555 MBq within 6 months post RAI therapy were similar. >Conclusion: SRAI is highly effective for the treatment of hyperthyroidism, with a cure rate of 100%. However, it has proved impossible to determine a fixed dose regimen for individual patients accurately to guarantee an euthyroid state. This is because hypothyroidism is a natural predictable sequel of RAI therapy. >Conflict of interest:None declared.
机译:>目标:近年来,使用放射性碘(RAI)作为格雷夫斯甲状腺功能亢进症的一线疗法和复发性格雷夫斯病的治疗选择越来越多。但是,关于最合适的剂量使用尚无共识。因此,本研究旨在确定甲亢对固定剂量的370 MBq和555 MBq RAI治疗的反应,并确定治疗后6个月甲减的发生率。>方法:甲亢患者接受放射性碘治疗的病例记录回顾性研究以确定两种固定剂量方案对甲状腺功能亢进的反应率。使用SPSS 15.0版进行统计分析,统计显着性水平设为p <0.05。 40名受试者中,有6名男性(15%)和34名女性(85%)因Graves甲亢而接受了RAI治疗,平均年龄为49.4岁(范围为25-75岁)。所有受试者在治疗后6个月的甲状腺功能状态均可用。 24例患者(60%)接受了370 MBqq,而16例患者(40%)接受了555 MBq。>结果:固定剂量370 MBq和555 MBq的反应相似(100%)。同样,在RAI治疗后的6个月内,这些受试者的甲状腺功能减退发生率分别为66.6%(固定剂量为370 MBq)和62.5%(固定剂量为555 MBq)。 >结论: SRAI对甲状腺功能亢进症非常有效,治愈率为100%。然而,事实证明不可能为每个患者准确地确定固定剂量方案以保证甲状腺功能正常。这是因为甲状腺功能减退是RAI治疗的自然可预测的后遗症。 >利益冲突:未声明。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号